Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
17-18 February, 2026
Village de la ChimieVillage de la Chimie
Not Confirmed
Not Confirmed
18-19 February, 2026
Linear SPPS vs Conjuga...Linear SPPS vs Conjugation of SPPS
Not Confirmed
Not Confirmed
18 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioAsia
Not Confirmed
Contact SupplierBioAsia
Industry Trade Show
Not Confirmed
17-18 February, 2026
Village de la ChimieVillage de la Chimie
Industry Trade Show
Not Confirmed
18-19 February, 2026
Linear SPPS vs Conjuga...Linear SPPS vs Conjugation of SPPS
Industry Trade Show
Not Confirmed
18 February, 2026
Digital content
NEWS #PharmaBuzz
19 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/19/3208767/35575/en/Aptose-Biosciences-Announces-Rescheduling-of-Special-Meeting-of-Shareholders-to-Approve-the-Acquisition-by-Hanmi-Pending-Final-Clearance-from-SEC.html
06 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/06/3201046/35575/en/Aptose-s-Tuspetinib-Triple-Drug-Therapy-Featured-at-the-2025-ASH-Annual-Meeting-High-Rate-of-Frontline-Clinical-Responses-Continues-Across-AML-Populations.html
19 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/19/3190597/35575/en/Aptose-Biosciences-Announces-Arrangement-Agreement-for-Acquisition-by-Hanmi-Pharmaceutical.html
13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187912/35575/en/Aptose-Reports-Third-Quarter-2025-Results.html
03 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/03/3179367/35575/en/Aptose-Tuspetinib-Clinical-Data-from-Ongoing-TUSCANY-Trial-in-Newly-Diagnosed-AML-Selected-for-Presentation-at-the-2025-ASH-Annual-Meeting.html
16 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/16/3167802/35575/en/Aptose-s-Tuspetinib-Exceeds-Expectations-When-Combined-with-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML.html
Drugs in Development
Details:
Under the acquisition of Tuspetinib, the deal aims to advance treatment for acute myeloid leukemia by targeting FLT3/JAK1/JAK2.
Lead Product(s): Tuspetinib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Brand Name: HM43239
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Hanmi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 19, 2025
Lead Product(s) : Tuspetinib,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Hanmi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Aptose Biosciences Announces Acquisition by Hanmi Pharmaceutical
Details : Under the acquisition of Tuspetinib, the deal aims to advance treatment for acute myeloid leukemia by targeting FLT3/JAK1/JAK2.
Product Name : HM43239
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 19, 2025
Details:
Tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases.
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: HM43239
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Hanmi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 22, 2025
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Hanmi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Financing
Aptose and Hanmi Extend Loan Agreement to Continue Development of Tuspetinib
Details : Tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases.
Product Name : HM43239
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 22, 2025
Details:
HM43239 (tuspetinib) is an oral myeloid kinome inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2025
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose Updates Tuspetinib Triple Therapy Trial in Newly Diagnosed AML
Details : HM43239 (tuspetinib) is an oral myeloid kinome inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2025
Details:
HM43239 (tuspetinib) is an oral myeloid kinome inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2025
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose Gets Approval for Dosing Escalation in Tuspetinib Trial
Details : HM43239 (tuspetinib) is an oral myeloid kinome inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2025
Details:
HM43239 (tuspetinib), an oral Myeloid Kinome Inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose’s Tuspetinib Shows Promising Frontline Results in AML Phase 1/2
Details : HM43239 (tuspetinib), an oral Myeloid Kinome Inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2025
Details:
HM43239 (tuspetinib), an oral Myeloid Kinome Inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose Doses First AML Patients with Tuspetinib in TUSCANY Trial
Details : HM43239 (tuspetinib), an oral Myeloid Kinome Inhibitor, is being investigated in combination with venetoclax and azacitidine as a frontline therapy for patients newly diagnosed with AML.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2025
Details:
Under the agreement, the NCI and Aptose will collaborate on the clinical development of HM43239 (tuspetinib), an inhibitor of key signaling kinases involved in r/r acute myeloid leukemia.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: The Division of Cancer Treatment and Diagnosis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 03, 2024
Lead Product(s) : Tuspetinib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Agreement
Aptose & NCI CRADA to Develop Tuspetinib for AML/MDS in MyeloMATCH Trials
Details : Under the agreement, the NCI and Aptose will collaborate on the clinical development of HM43239 (tuspetinib), an inhibitor of key signaling kinases involved in r/r acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 03, 2024
Details:
HM43239 (tuspetinib), a highly differentiated oral kinase inhibitor beng developed in combination therapy with azacitidine (AZA) and venetoclax for acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2024
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose Initiates TUSCANY Study for Tuspetinib Triplet Therapy in Newly Diagnosed AML
Details : HM43239 (tuspetinib), a highly differentiated oral kinase inhibitor beng developed in combination therapy with azacitidine (AZA) and venetoclax for acute myeloid leukemia (AML).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2024
Details:
Aptose will use the proceeds from such loan for the development of HM43239 (tuspetinib), a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Hanmi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 30, 2024
Lead Product(s) : Tuspetinib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Hanmi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Financing
Aptose Receives $10M and Negotiates Partnership with Hanmi For Tuspetinib
Details : Aptose will use the proceeds from such loan for the development of HM43239 (tuspetinib), a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 30, 2024
Details:
The net proceeds will be used for the manufacturing and clinical trials of potent inhibitor known as HM43239 (tuspetinib) for patients with relapsed or refractory acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Hanmi Pharmaceutical
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Lead Product(s) : Tuspetinib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Hanmi Pharmaceutical
Deal Size : $13.7 million
Deal Type : Public Offering
Aptose Closes $9.7 Mn Offering and $4 Mn Private Placement with Hanmi Pharmaceutical
Details : The net proceeds will be used for the manufacturing and clinical trials of potent inhibitor known as HM43239 (tuspetinib) for patients with relapsed or refractory acute myeloid leukemia (AML).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 31, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
